BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
49.60
-0.26 (-0.52%)
At close: 4:01PM EDT

49.65 +0.05 (0.10%)
After hours: 7:23PM EDT

Stock chart is not supported by your current browser
Previous Close49.86
Open50.01
Bid49.55 x 800
Ask49.65 x 2900
Day's Range49.47 - 50.11
52 Week Range44.30 - 67.16
Volume11,327,638
Avg. Volume18,885,726
Market Cap80.979B
Beta (3Y Monthly)0.86
PE Ratio (TTM)16.48
EPS (TTM)3.01
Earnings DateApr 25, 2019
Forward Dividend & Yield1.64 (3.28%)
Ex-Dividend Date2019-01-03
1y Target Est56.70
Trade prices are not sourced from all markets
  • Analysts Have Revised BMY’s Target Price Downward in March
    Market Realist6 hours ago

    Analysts Have Revised BMY’s Target Price Downward in March

    How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceAnalysts expect an upside potential of 13.72% for Bristol-Myers Squibb (BMY) based on the company’s closing price on

  • Barrons.com7 hours ago

    Starboard Is Against the Bristol-Myers and Celgene Deal. Now It Gets Interesting.

    Less than a month before shareholders vote on Bristol-Myers Squibb’s proposed take over of Celgene, activist hedge fund Starboard Value released a presentation detailing its opposition to the deal.

  • TheStreet.com8 hours ago

    Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

    traded blows with activist investor Starboard Value LP Tuesday as the pair issued competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene Corp. Bristol Myers said the deal, which if first unveiled in early January, would mean give combined companies number one positions in oncology and cardiovascular drug sales, with a top five standing in immunology and inflammation and nine currency products with over $1 billion in sales. Starboard, for its part, opposes the deal, arguing Celgene is a company facing a "massive patent cliff" that will force it to replace some 60% of its revenues over the next seven years.

  • Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer
    Zacks9 hours ago

    Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

    Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

  • TheStreet.com11 hours ago

    Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

    posted a wider-than-expected fourth quarter loss but said sales nearly tripled in a growing global market for medical marijuana. Tilray said earnings for the three months ending in December were pegged at a net loss of 33 cents per share, compared to a 4 cents per share profit from the same period in 2017, a figure it put down to "operating expenses related to growth initiatives, expansion of international teams and costs related to financings and M&A activities." Group sales, however, rose more than 200% to $15.5 million, while total kilogram equivalents increased nearly three-fold to 2,053 and the average net selling price rose 5.5% to $7.52 per gram, reported TheStreet's Martin Baccardax. Elon Musk is still in hot water with the SEC about his Twitter presence.

  • Bristol-Myers Squibb and Starboard Value square off over Celgene deal
    American City Business Journals11 hours ago

    Bristol-Myers Squibb and Starboard Value square off over Celgene deal

    Activist investor says Bristol-Myers' Celgene deal "is ill-advised and could destroy substantial value for shareholders"; Bristol-Myers argues the deal "is a financially and strategically compelling transaction."

  • Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
    Zacks13 hours ago

    Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

    Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

  • PR Newswire14 hours ago

    Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition of Celgene

    Mails Definitive Proxy Materials and a BLUE Proxy Card for Shareholders to Vote AGAINST the Proposed Transaction at the Upcoming Special Meeting Believes the Proposed Merger with Celgene is Not in the ...

  • Business Wire14 hours ago

    Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene

    Bristol-Myers Squibb Company (BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celgene Corporation (CELG). The investor presentation is available on the SEC’s website at www.SEC.gov and on Bristol-Myers Squibb’s website at https://www.bms.com/investors.html. The Celgene acquisition is a financially and strategically compelling transaction.

  • Reuters23 hours ago

    U.S. FDA approves Roche's small cell lung cancer treatment

    Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb. The U.S. Food and Drug Administration (FDA) approved Tecentriq plus chemotherapy for untreated extensive-stage small cell lung cancer (SCLC), after a study showed patients getting the drug cocktail lived a median 12.3 months, compared to 10.3 months for those getting chemotherapy alone, Genentech said in a statement.

  • Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
    Zacksyesterday

    Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

    Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).

  • Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
    Zacksyesterday

    Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

    Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

  • AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention
    Business Wire2 days ago

    AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention

    AUGUSTUS is the largest trial in this high-risk patient population requiring both anticoagulant and antiplatelet therapies

  • Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
    Motley Fool4 days ago

    Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?

    This mega-merger could be on the rocks following objections by high-profile investors.

  • Infinity Inks Deal With Roche for Phase II Study of IPI-549
    Zacks4 days ago

    Infinity Inks Deal With Roche for Phase II Study of IPI-549

    Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.

  • Merck's Keytruda Gets EU Approval for Difficult Lung Cancer
    Zacks4 days ago

    Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

    Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.

  • Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
    Zacks4 days ago

    Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

    Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.

  • Some Bristol-Myers Squibb (NYSE:BMY) Shareholders Are Down 25%
    Simply Wall St.4 days ago

    Some Bristol-Myers Squibb (NYSE:BMY) Shareholders Are Down 25%

    The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do both better or worse than that.Read More...

  • J&J Seeks Approval for Darzalex in Expanded Patient Group
    Zacks5 days ago

    J&J Seeks Approval for Darzalex in Expanded Patient Group

    J&J (JNJ) files sBLA seeking approval for Darzalex combination regimen in newly- diagnosed, transplant ineligible multiple myeloma patient population.

  • Reuters5 days ago

    U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

    The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid. Shares of Celgene were up 1.2 percent at $88.33 in early trading. The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was denying Alvogen's petition for an inter-partes review on the patents of the drug.

  • Reuters5 days ago

    U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid

    A U.S. administrative court on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid. The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was denying Alvogen's petition for an inter-partes review on the patents of the drug. Drugmaker Bristol-Myers Squibb Co in January said it would buy Celgene Corporation for about $74 billion, to expand its pipeline of cancer drugs.

  • GuruFocus.com6 days ago

    5 Biotech Stocks to Keep an Eye on in 2019

    The biotech sector is an interesting one to follow. Warning! GuruFocus has detected 2 Warning Sign with CELG. There has been quite a bit of chatter recently surrounding the potential acquisition of the company by Bristol-Myers Squibb (BMY).

  • Barrons.com6 days ago

    Celgene’s Positive Drug Data Bolsters Bristol-Myers Deal, Analyst Says

    Robert W. Baird analyst Brian Skorney wrote that neither company is “a coveted prize, but both are better off together than apart.” Celgene stock is up on upbeat FDA actions.

  • Barrons.com6 days ago

    A Merck Cancer Treatment Has a Big Opportunity in China, Analyst Says

    Cantor’s Louise Chen says the potential for Merck’s Keytruda in China could equate to billions of dollars not yet in forecasts.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.

    Bristol-Myers Squibb Co NYSE:BMYView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low and declining Bearish sentimentShort interest | PositiveShort interest is low for BMY with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 4. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BMY had net inflows of $4.43 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. BMY credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.